REG - ConvaTec Group PLC - AGM Special Resolutions at NSM

ConvaTecAnnouncement

11/05/2018 07:00

2018-05-11T06:00:02.238Zreuters.comtag:reuters.com,2018-05-11:newsml_RSK7343Na:13TXT
This file is provided for EAP sample purposes only; it's structure and detail are subject to change, and should not be used as a definitive reference for actual development and processing.2018-05-11T06:00:02.238Z2018-05-11T06:00:02.238Z____UCDP:parsn_lse_10.54.4.69_1.2.37235:2019-06-11T06:00:02.238Z3RSK7343NaREG - ConvaTec Group PLC  - AGM Special Resolutions at NSMHealthcare (TRBC level 1)Pharmaceuticals & Medical Research (TRBC level 2)LEGACY: Pharmaceuticals (TRBC level 3)LEGACY: Generic & Specialty Pharmaceuticals (TRBC)Proprietary & Advanced Pharmaceuticals (TRBC level 5)Pharmaceuticals (TRBC level 4)Western EuropeUnited KingdomEuropeSuggested SourcesNews AnnouncementsRegulatory Corporate News AnnouncementsCompany NewsEurope daily earnings hits & missesConvaTec Group PLC








RNS Number : 7343N
ConvaTec Group PLC
11 May 2018
 

 
Special Resolutions available at NSM
 
11 May 2018
 
ConvaTec Group Plc
 
ConvaTec Group Plc ("ConvaTec"), a leading global medical products and technologies company, held its annual general meeting on 10 May 2018 and the results of the poll were published that day.
 
In accordance with Listing Rule 9.6.2, copies of the resolutions that do not constitute ordinary business that were passed at the annual general meeting have been submitted to the National Storage Mechanism and will be available for inspection at www.morningstar.co.uk/uk/NSM.
 
For further information, please contact Clare Bates, Company Secretary (0118 952 8100).
 
About ConvaTec


ConvaTec is a global medical products and technologies company focused on therapies for the management of chronic conditions. The Company is listed on the London Stock Exchange (stock symbol: CTEC) and has leading market positions in advanced wound care, ostomy care, continence and critical care, and infusion devices. ConvaTec's products provide a range of clinical and economic benefits, including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care.  www.convatecgroup.com
 
 
 
Enquiries
 
Analysts and Investors
 
John Crosse, VP Investor Relations, ConvaTec                              +44 (0)7500 141 435
Kirsty Law, Director Investor Relations, ConvaTec                          +44 (0)7470 909 582
investorrelations@convatec.com
 
Media
 
Bobby Leach, VP Group Corporate Affairs, ConvaTec                    +44 (0)7770 842 226
Rebecca Fitchett, Finsbury                                                               +44 (0)207 251 3801


ConvaTec Group Plc's LEI code is 213800LS272L4FIDOH92
# # #
END



This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RAGGGUUUAUPRGBU